/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

BOLT BIOTHERAPEUTICS INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$5.17 0.0551(5.51%) BOLT at 04 Dec 2025 04:27 PM Biotechnology
Lowest Today 4.99
Highest Today 5.18
Today’s Open 4.99
Prev. Close 4.995
52 Week High 12.60
52 Week Low 4.41
Day’s Range: Low 4.99 High 5.18
52-Week Range: Low 4.41 High 12.60
1 day return -
1 Week return +8.65
1 month return +4.35
3 month return +4.35
6 month return -20.15
1 year return +820.84
3 year return +276.42
5 year return -
10 year return -

Institutional Holdings

Vivo Capital, LLC 9.17

TANG CAPITAL MANAGEMENT LLC 8.69

Sofinnova Ventures 7.18

Pivotal bioVenture Partners Investment Advisor LLC 4.93

Vanguard Group Inc 3.05

Samsara BioCapital, LLC 2.73

Vanguard Total Stock Mkt Idx Inv 2.46

Board of Ttees Leland Stanford Jr Univ 1.87

Pfizer Inc 1.63

Geode Capital Management, LLC 0.97

Renaissance Technologies Corp 0.95

Squarepoint Ops LLC 0.65

ADAR1 Capital Management LLC 0.56

BlackRock Inc 0.55

Vanguard Institutional Extnd Mkt Idx Tr 0.37

Fidelity Extended Market Index 0.36

Fidelity Total Market Index 0.28

Morgan Stanley - Brokerage Accounts 0.19

Spartan Extended Market Index Pool F 0.16

PGIM Quantitative Solutions US Micro Cap 0.12

Fidelity Series Total Market Index 0.09

Northern Trust Extended Eq Market Idx 0.07

NT Ext Equity Mkt Idx Fd - L 0.07

Extended Equity Market Fund K 0.06

Spartan Total Market Index Pool G 0.06

NT Ext Equity Mkt Idx Fd - NL 0.04

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.03

Goss Wealth Management LLC 0.03

Tower Research Capital LLC 0.02

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.02

NT Ext Eq Mkt Indx Fd DC Lend T3 0.02

Bank of America Corp 0.01

State St US Extended Mkt Indx NL Cl C 0.01

BNYM Mellon SL Market Completion UC1 0.01

UBS Group AG 0.01

Extended Equity Market Fund M 0.01

Fidelity Nasdaq Composite Index 0.01

FMR Inc 0.01

SSgA U.S. Total Market Index Strategy 0.01

JPMorgan Chase & Co 0.00

Market Status

Strong Buy: 1

Buy: 0

Hold: 3

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 9.59 M

PB Ratio 0.2968

PE Ratio 0.0

Enterprise Value 1.21 M

Total Assets 99.63 M

Volume 38575

Company Financials

Annual Revenue FY23:7198000 7.2M, FY22:5729000 5.7M, FY21:1260000 1.3M, FY20:231000 0.2M, FY19:215000 0.2M

Annual Profit FY23:null 0.0M, FY22:5729000 5.7M, FY21:1260000 1.3M, FY20:231000 0.2M, FY19:215000 0.2M

Annual Net worth FY23:-71291000 -71.3M, FY22:-85875000 -85.9M, FY21:-104394000 -104.4M, FY20:-72274000 -72.3M, FY19:-30005000 -30.0M

Quarterly Revenue Q3/2025:2169000 2.2M, Q2/2025:1804000 1.8M, Q1/2025:1222000 1.2M, Q3/2024:1141000 1.1M, Q2/2024:1275000 1.3M

Quarterly Profit Q3/2025:1879000 1.9M, Q2/2025:1804000 1.8M, Q1/2025:1222000 1.2M, Q3/2024:1141000 1.1M, Q2/2024:-14158000 -14.2M

Quarterly Net worth Q3/2025:-7144000 -7.1M, Q2/2025:-8561000 -8.6M, Q1/2025:-11040000 -11.0M, Q3/2024:-15176000 -15.2M, Q2/2024:-21195000 -21.2M

Fund house & investment objective

Company Information Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform that targets claudin 18.2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc.; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Organisation Biotechnology

Employees 40

Industry Biotechnology

CEO Mr. William P. Quinn

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow